Infant Protection Against Respiratory Syncytial Virus (RSV) by Maternal RSV Vaccination or Receipt of RSV Monoclonal Antibody, and Intent for RSV Monoclonal Antibody Receipt Reported by Females Aged 18-49 Years Who Have an Infant <8 Months During the RSV

• Infant Protection Against RSV by Maternal RSV Vaccination or Receipt of Monoclonal Antibody, and Intent for RSV Monoclonal Antibody Receipt, Reported by Females Aged 18-49 Years Who Have an Infant <8 Months During the RSV Season (Born Since April 1, 2025), by Month of Interview • Monthly estimates of infant protection against RSV by maternal RSV vaccination or infant receipt of RSV monoclonal antibody (nirsevimab or clesrovimab), as well as intent for RSV monoclonal antibody receipt, were calculated using data from the National Immunization Surveys (NIS) – Fall Respiratory Virus Module (NIS–FRVM). The NIS–FRVM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older. Data were reported by adult females aged 18–49 years with infants under the age of 8 months during the RSV season (born since April 1, 2025). All estimates are based upon parent-reported receipt of RSV monoclonal antibody.